Article | Published:

Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis due to the lack of an effective targeted therapy. Histone lysine methyltransferases (KMTs) have emerged as attractive drug targets for cancer therapy. However, the function of the majority of KMTs in TNBC has remained largely unknown. In the current study, we found that KMT nuclear receptor binding SET domain protein 2 (NSD2) is overexpressed in TNBC tumors and that its overexpression is associated with poor survival of TNBC patients. NSD2 regulates TNBC cell survival and invasion and is required for tumorigenesis and tumor growth. Mechanistically, NSD2 directly controls the expression of EGFR and ADAM9, a member of the ADAM (a disintegrin and metalloproteinase) family that mediates the release of growth factors, such as HB-EGF. Through its methylase activity, NSD2 overexpression stimulates EGFR-AKT signaling and promotes TNBC cell resistance to the EGFR inhibitor gefitinib. Together, our results identify NSD2 as a major epigenetic regulator in TNBC and provide a rationale for targeting NSD2 alone or in combination with EGFR inhibitors as a targeted therapy for TNBC.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease [Review Article]. Nat Rev Clin Oncol. 2016;13:674.

  2. 2.

    Carey LA, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30:2615–23.

  3. 3.

    Nakai K, Hung M-C, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016;6:1609–23.

  4. 4.

    Costa R, et al. Targeting epidermal growth factor receptor in triple negative breast cancer: new discoveries and practical insights for drug development. Cancer Treat Rev. 2017;53:111–19.

  5. 5.

    Blanchot-Jossic F, et al. Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol. 2005;207:156–63.

  6. 6.

    Al-Ejeh F, et al. Treatment of triple-negative breast cancer using anti-EGFR–directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J Nucl Med. 2013;54:913–21.

  7. 7.

    Zhao Y., et al. TGF-β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathway. Molecular Oncology 2018;12:305–321.

  8. 8.

    Jin W, et al. TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. Mol Cell Biol. 2012;32:50–63.

  9. 9.

    Ramnarain DB, et al. RIP1 links inflammatory and growth factor signaling pathways by regulating expression of the EGFR [Original Paper]. Cell Death Differ. 2007;15:344.

  10. 10.

    Li L, et al. ZNF516 suppresses EGFR by targeting the CtBP/LSD1/CoREST complex to chromatin. Nat Commun. 2017;8:691.

  11. 11.

    Yang P, et al. Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol. 2012;32:3121–31.

  12. 12.

    Kuo AJ, et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell. 2011;44:609–20.

  13. 13.

    Marango J, et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood. 2008;111:3145–54.

  14. 14.

    Martinez-Garcia E, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood. 2011;117:211–20.

  15. 15.

    Nimura K, et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature. 2009;460:287–91. eng.

  16. 16.

    Lauring J, et al. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood. 2008;111:856–64. eng.

  17. 17.

    Huang Z, et al. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma. Cancer Res. 2013;73:6277–88.

  18. 18.

    Hudlebusch HR, et al. MMSET is highly expressed and associated with aggressiveness in neuroblastoma. Cancer Res. 2011;71:4226–35. eng.

  19. 19.

    Hudlebusch HR, et al. The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin Cancer Res. 2011;17:2919–33.

  20. 20.

    Kalashnikova EV, et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 2010;70:9402–12.

  21. 21.

    Zou JX, et al. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance. Mol Cancer Res. 2014;12:539.

  22. 22.

    Toyokawa G, et al. Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia. 2011;13:887–98.

  23. 23.

    Wang J, et al. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Cancer Lett. 2016;378:69–79.

  24. 24.

    Fischer OM, Hart S, Gschwind A, Prenzel N, Ullrich A. Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol. 2004;24:5172–83.

  25. 25.

    Liu R, et al. DNMT1–microRNA126 epigenetic circuit contributes to esophageal squamous cell carcinoma growth via ADAM9–EGFR–AKT signaling. Clin Cancer Res. 2015;21:854–63.

  26. 26.

    Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. New Engl J Med. 2008;358:1160–74.

  27. 27.

    Itabashi H, et al. Angiotensin II and epidermal growth factor receptor cross-talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines. Hepatol Res. 2008;38:601–13.

  28. 28.

    Coussens NP, et al. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2. J Biol Chem. 2018;293:13750–65.

  29. 29.

    Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009;8:724–32.

  30. 30.

    Tian X, et al. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets. 2013;13:558–79.

  31. 31.

    Wagner T, Jung M. New lysine methyltransferase drug targets in cancer. Nat Biotech. 2012;30:622–23.

  32. 32.

    Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol. 2009;2009:567486.

  33. 33.

    Williams CB, Soloff AC, Ethier SP, Yeh ES. Chapter seven—perspectives on epidermal growth factor receptor regulation in triple-negative breast cancer: ligand-mediated mechanisms of receptor regulation and potential for clinical targeting. Advances in cancer research. 2015;127:253–281

  34. 34.

    Nagaya T, et al. Near infrared photoimmunotherapy targeting EGFR positive triple negative breast cancer: optimizing the conjugate-light regimen. PLoS One. 2015;10:e0136829.

  35. 35.

    Sun S, Zhou X, Zhang W, Gallick Gary E, Kuang J. Unravelling the pivotal role of Alix in MVB sorting and silencing of the activated EGFR. Biochem J. 2015;466:475–87.

Download references

Acknowledgements

This work was supported in part by grants from the NIH R01DK060019 and R01CA206222 to Hong-Wu Chen, the National Natural Science Foundation of China (No. 81673037) and the Department of Education, Guangdong Government under the Top-tier University Development Scheme for Research and Control of Infectious Diseases (No. 2015017) to Jian-zhen Xu, the National Natural Science Foundation of China (No. 81373655) to Hai-bin Wang and National Natural Science Foundation of China (No. 81872891) to Jun-jian Wang.

Author contributions

H.-W.C. and J.W. conceived the research. H.-W.C. and J.W. designed the research. J.W., P.C., Z.D., H.W. and J.X.Z. performed research. H.-W.C., J.W., J.X.Z. and H.-B.W. analyzed the data. H.-W.C., J.W., P.L. and J.X.Z. wrote and/or edited the manuscript.

Author information

Correspondence to Jian-Zhen Xu or Hong-Wu Chen.

Electronic supplementary material

Supplemental Figures

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • NSD2
  • Cell survival
  • Cell invasion
  • Histone methyltransferase
  • Triple-negative breast cancer
  • EGFR
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7